Literature DB >> 23032305

The TaqIA RFLP is associated with attenuated intervention-induced body weight loss and increased carbohydrate intake in post-menopausal obese women.

Jameason D Cameron1, Marie-Ève Riou1, Frédérique Tesson2, Gary S Goldfield3, Rémi Rabasa-Lhoret4, Martin Brochu5, Éric Doucet6.   

Abstract

INTRODUCTION: Polymorphisms of the dopamine receptor D2 (DRD2) gene have been associated with obesity phenotypes. Our aim was to examine if the genotype of TaqIA Restriction Fragment Length Polymorphism (RFPL) was related to an attenuated weight loss response or to changes in energy expenditure (EE) and food preference before and after weight loss. methods: Obese post-menopausal women (age=57.1 ± 4.6 yr, weight=85.4 ± 15.4 kg and BMI=32.8 ± 4.5 kg/m(2)) were genotyped for TaqIA (n=127) by using PCR-RFLP analysis and categorized as possessing at least one copy of the A1 allele (A1(+)) or no copy (A1(-)). Women were randomized into two groups, caloric restriction (CR) and caloric restriction+resistance training (CRRT) and in this study were further classified as follows: A1(+)CR, A1(+)CRRT, A1-(-)CR and (-)A1(-)CRRT. Body composition, total daily EE, physical activity EE, Resting EE (REE), and energy intake were obtained at baseline and post-intervention using DXA, doubly-labeled water, indirect calorimetry, and 3-day dietary records, respectively.
RESULTS: Overall, all of the anthropometric variables and REE significantly decreased post-intervention (p<0.001). Women in the CRRT group lost significantly more fat mass (FM) than the CR women (p<0.05). There were significant time by group by allele interactions for attenuated body weight (BW), BMI, and FM loss for A1(+) (vs. A1(-)) in CRRT (p<0.05) and for increased % carbohydrate intake (p<0.01).
CONCLUSION: TaqIA genotype was associated with body weight loss post-intervention; more specifically, carriers of the A1 allele lost significantly less BW and FM than the A1(-) and had increased carbohydrate intake in the CRRT group.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23032305      PMCID: PMC3934842          DOI: 10.1016/j.appet.2012.09.010

Source DB:  PubMed          Journal:  Appetite        ISSN: 0195-6663            Impact factor:   3.868


  53 in total

1.  Association of dopamine D2 receptor polymorphisms Ser311Cys and TaqIA with obesity or type 2 diabetes mellitus in Pima Indians.

Authors:  C P Jenkinson; R Hanson; K Cray; C Wiedrich; W C Knowler; C Bogardus; L Baier
Journal:  Int J Obes Relat Metab Disord       Date:  2000-10

Review 2.  Gene-exercise interactions.

Authors:  Tuomo Rankinen; Claude Bouchard
Journal:  Prog Mol Biol Transl Sci       Date:  2012       Impact factor: 3.622

3.  The TaqIA polymorphism linked to the DRD2 gene is related to lower attention and less inhibitory control in alcoholic patients.

Authors:  R Rodríguez-Jiménez; C Avila; G Ponce; M I Ibáñez; G Rubio; M A Jiménez-Arriero; I Ampuero; J A Ramos; J Hoenicka; T Palomo
Journal:  Eur Psychiatry       Date:  2005-08-31       Impact factor: 5.361

4.  Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers.

Authors:  E G Jönsson; M M Nöthen; F Grünhage; L Farde; Y Nakashima; P Propping; G C Sedvall
Journal:  Mol Psychiatry       Date:  1999-05       Impact factor: 15.992

5.  Interindividual variation in posture allocation: possible role in human obesity.

Authors:  James A Levine; Lorraine M Lanningham-Foster; Shelly K McCrady; Alisa C Krizan; Leslie R Olson; Paul H Kane; Michael D Jensen; Matthew M Clark
Journal:  Science       Date:  2005-01-28       Impact factor: 47.728

6.  Brain dopamine and obesity.

Authors:  G J Wang; N D Volkow; J Logan; N R Pappas; C T Wong; W Zhu; N Netusil; J S Fowler
Journal:  Lancet       Date:  2001-02-03       Impact factor: 79.321

7.  A comparison of the effects of olanzapine and risperidone versus placebo on eating behaviors.

Authors:  James L Roerig; James E Mitchell; Martina de Zwaan; Ross D Crosby; Blake A Gosnell; Kristine J Steffen; Stephen A Wonderlich
Journal:  J Clin Psychopharmacol       Date:  2005-10       Impact factor: 3.153

Review 8.  Addiction and its reward process through polymorphisms of the D2 dopamine receptor gene: a review.

Authors:  E P Noble
Journal:  Eur Psychiatry       Date:  2000-03       Impact factor: 5.361

Review 9.  [Psychotropic drugs induced weight gain: a review of the literature concerning epidemiological data, mechanisms and management].

Authors:  O Ruetsch; A Viala; H Bardou; P Martin; M N Vacheron
Journal:  Encephale       Date:  2005 Jul-Aug       Impact factor: 1.291

10.  Relationships between the taqI polymorphism of the dopamine D2 receptor and blood pressure in hyperglycaemic and normoglycaemic Chinese subjects.

Authors:  G N Thomas; J A Critchley; B Tomlinson; C S Cockram; J C Chan
Journal:  Clin Endocrinol (Oxf)       Date:  2001-11       Impact factor: 3.478

View more
  12 in total

Review 1.  Personalized weight loss strategies-the role of macronutrient distribution.

Authors:  J Alfredo Martinez; Santiago Navas-Carretero; Wim H M Saris; Arne Astrup
Journal:  Nat Rev Endocrinol       Date:  2014-10-14       Impact factor: 43.330

2.  Relation of the multilocus genetic composite reflecting high dopamine signaling capacity to future increases in BMI.

Authors:  Sonja Yokum; C Nathan Marti; Andrew Smolen; Eric Stice
Journal:  Appetite       Date:  2014-12-15       Impact factor: 3.868

3.  The effect of the ANKK1/DRD2 Taq1A polymorphism on weight changes of dopaminergic treatment in prolactinomas.

Authors:  A P Athanasoulia; C Sievers; M Uhr; M Ising; G K Stalla; H J Schneider
Journal:  Pituitary       Date:  2014-06       Impact factor: 4.107

Review 4.  DRD2: Bridging the Genome and Ingestive Behavior.

Authors:  Xue Sun; Serge Luquet; Dana M Small
Journal:  Trends Cogn Sci       Date:  2017-03-31       Impact factor: 20.229

5.  Associations of the ANKK1 and DRD2 gene polymorphisms with overweight, obesity and hedonic hunger among women from the Northwest of Iran.

Authors:  Fereshteh Aliasghari; Saba A Nazm; Sepideh Yasari; Reza Mahdavi; Morteza Bonyadi
Journal:  Eat Weight Disord       Date:  2020-02-04       Impact factor: 4.652

6.  Impact of the DRD2 Polymorphisms on the Effectiveness of the Training Program.

Authors:  Katarzyna Świtała; Aleksandra Bojarczuk; Jacek Hajto; Marcin Piechota; Maciej Buryta; Agata Leońska-Duniec
Journal:  Int J Environ Res Public Health       Date:  2022-04-19       Impact factor: 3.390

7.  Weight-loss response to naltrexone/bupropion is modulated by the Taq1A genetic variant near DRD2 (rs1800497): A pilot study.

Authors:  Jamie A Mullally; Wendy K Chung; Charles A LeDuc; Tirissa J Reid; Gerardo Febres; Steven Holleran; Rajasekhar Ramakrishnan; Judith Korner
Journal:  Diabetes Obes Metab       Date:  2021-01-08       Impact factor: 6.408

Review 8.  Dopamine and glucose, obesity, and reward deficiency syndrome.

Authors:  Kenneth Blum; Panayotis K Thanos; Mark S Gold
Journal:  Front Psychol       Date:  2014-09-17

Review 9.  Hatching the behavioral addiction egg: Reward Deficiency Solution System (RDSS)™ as a function of dopaminergic neurogenetics and brain functional connectivity linking all addictions under a common rubric.

Authors:  Kenneth Blum; Marcelo Febo; Thomas McLaughlin; Frans J Cronjé; David Han; S Mark Gold
Journal:  J Behav Addict       Date:  2014-08-26       Impact factor: 6.756

Review 10.  A meta-analysis of the relationship between brain dopamine receptors and obesity: a matter of changes in behavior rather than food addiction?

Authors:  D Benton; H A Young
Journal:  Int J Obes (Lond)       Date:  2016-03       Impact factor: 5.095

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.